HNHA
Based on 1 Customer Validation
HNHA is a potent HDAC inhibitor with an IC50 of 100 nM. HNHA arrests the cell cycle at the G1/S phase via p21 induction. HNHA inhibits tumor growth and tumor neovascularization. HNHA may be a potent anti-cancer agent against breast cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.71%
- No. CAS: 926908-04-5
- Fòrmula: C17H21NO2S
- Peso molecular:303.42
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-13322
PracinostatHDAC/MBLAC2 Inhibitor -
HY-13265
AR-42Pan HDAC Inhibitor -
HY-12163
EntinostatHDAC Class I Inhibitor -
HY-10221
VorinostatHDAC Inhibitor -
HY-13606
DacinostatAutophagy Inducer -
HY-16026
RicolinostatHDAC6 Inhibitor -
HY-13216
PyroxamideHDAC1 Inhibitor -
HY-18360
TMP269HDACIIa Inhibitor -
HY-19350
BML-210HDAC Inhibitor -
HY-18976
UF010HDAC Inhibitor -
HY-10221R
Vorinostat (Standard)HDAC Inhibitor -
HY-19348
Pimelic Diphenylamide 106HDAC Inhibitor
Actividad biológica
Descripciòn
IC50 & Target
|
MMP-2 |
MMP-9 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-1080 | IC50 |
3 μM
Compound: HNHA
|
Cytotoxicity against human HT1080 cells
Cytotoxicity against human HT1080 cells
|
[PMID: 23953690] |
In Vitro
HNHA (0-100 μM, 96 h) shows strong inhibition at lower concentrations on cancer cell lines, especially on breast cancer cells, mouse FM3A and human MCF-7[1].
HNHA (15 μM, 24 h) arrests cancer cells at the G1/S phase of the cell cycle, activates p21and rescues strongly protein acetylation[1].
HNHA (15 μM, 12 h) inhibits angiogenic proteins in breast cancer cells, effectively inactivates MMP-2, MMP-9, VEGF and HIF-1α[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:FM3A, C1300, LA-N-1, LA-N-2, LA-N-5, NB16, NB19, NB69, SK-N-SH, MCF-7 and HT-29[1]
-
Concentration:0-100 μM
-
Incubation Time:96 h
-
Result:Showed strong inhibition at lower concentrations on all cancer cell lines (FM3A, C1300, LA-N-1, LA-N-2, LA-N-5, NB16, NB19, NB69, SK-N-SH, MCF-7 and HT-29), with IC50 values of 15.70, 55.63, 22.78, 23.18, 26.70, 19.64, 21.26, 22.31, 65.09, 14.33, and 16.98 μM, respectively.
-
Cell Line:FM3A and MCF-7[1]
-
Concentration:0, 0.1, 1, 5, 10, 15, 20, 25,30 μM
-
Incubation Time:48 h
-
Result:Showed dose-dependent inhibition of viability in mouse and human breast cancer cells.
-
Cell Line:FM3A and MCF-7 cells[1]
-
Concentration:15 μM
-
Incubation Time:24 h
-
Result:Arrested FM3A and MCF-7 cells in the G1/S phase.
-
Cell Line:FM3A and MCF-7 cells[1]
-
Concentration:0, 0.1, 1, 10, and 20 μM (24 h)
-
Incubation Time:1, 6, 24, 48, and 72 h (15 μM)
-
Result:Activated a cell proliferation arrestor p21, increased histone and non-histone protein acetylation and inhibited FM3A and MCF-7 proliferation in vitro, and was very effective in increasing the acetylation level of histone H3 protein in FM3A and MCF-7. The most effective dose point for acetylation of histone H3 was 10-20 μM. Histone H3 acetylation peaked after 1 h of exposure to the drugs and remained stable for 1-6 h.
-
Cell Line:FM3A and MCF-7 cells[1]
-
Concentration:15 μM
-
Incubation Time:12 h
-
Result:Showed a strong induction of TIMP-1 and TIMP-2, and effectively inactivated MMP-2, MMP-9, VEGF and HIF-1α.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C3H/HeJ-FasL mice (FM3A breast cancer cell tumor xenograft, 6 weeks, n = 25/group)[1]
-
Dosage:20 μM/mouse
-
Administration:IP, once every 2 days for a total of six injections
-
Result:Reduced tumor burden and extended the survival rate. Effectively inhibited cancer development and angiogenesis in vivo. Increased TIMP-1, TIMP-2 and p21, decreased MMP-2, MMP-9, HIF-1α and VEGF protein expression, and reduced the distribution of CD34, HIF-1α and VEGF.
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Flow cytometric DNA-content cell-cycle staining
- BrdU Incorporation Assay
- Patient-Derived Xenograft (PDX)
- Patient-Derived Orthotopic Xenograft (PDOX)
- Protocol for Cell Cycle
- Subcutaneous Cell-Line-Derived Xenograft
- Breast Cancer Modeling
- Orthotopic Cell-Line Xenograft
Chemical Information
-
No. CAS 926908-04-5
-
Appearance Solid
-
Peso molecular 303.42
-
Fòrmula C17H21NO2S
-
Color White to off-white
-
SMILES
O=C(NO)CCCCCCSC1=CC=C2C=CC=CC2=C1
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
In Vitro:
DMSO : 100 mg/mL (329.58 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (273 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2958 mL | 16.4788 mL | 32.9576 mL | 82.3940 mL |
| 5 mM | 0.6592 mL | 3.2958 mL | 6.5915 mL | 16.4788 mL | |
| 10 mM | 0.3296 mL | 1.6479 mL | 3.2958 mL | 8.2394 mL | |
| 15 mM | 0.2197 mL | 1.0986 mL | 2.1972 mL | 5.4929 mL | |
| 20 mM | 0.1648 mL | 0.8239 mL | 1.6479 mL | 4.1197 mL | |
| 25 mM | 0.1318 mL | 0.6592 mL | 1.3183 mL | 3.2958 mL | |
| 30 mM | 0.1099 mL | 0.5493 mL | 1.0986 mL | 2.7465 mL | |
| 40 mM | 0.0824 mL | 0.4120 mL | 0.8239 mL | 2.0599 mL | |
| 50 mM | 0.0659 mL | 0.3296 mL | 0.6592 mL | 1.6479 mL | |
| 60 mM | 0.0549 mL | 0.2746 mL | 0.5493 mL | 1.3732 mL | |
| 80 mM | 0.0412 mL | 0.2060 mL | 0.4120 mL | 1.0299 mL | |
| 100 mM | 0.0330 mL | 0.1648 mL | 0.3296 mL | 0.8239 mL |
HNHA Related Classifications
HY-118672 Related Classifications
Powered by Bioz